IND-enabling ADME studies to predict drug-drug interaction.
Testing for mRNA and enzyme activity for a comprehensive portfolio of inducible enzymes, including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, UGTs and transporters
In vitro inhibition testing for a range of drug metabolizing enzymes, including CYPs (reversible and TDI), UGTs, Oxidases (e.g., AO, MAO), and Esterases (e.g., CES, ChE)
Comprehensive Phase I/II (CYP, UGT, AO/XO, FMO, CES, SULT) enzyme identification using Gentest Supersomes®, human liver fractions and human hepatocytes, including enzyme kinetics (Km, CLint) and fm determination (selective chemical inhibition, RAF/ISEF scaling)
Customized ADME analyses on unusual drug metabolizing enzymes, screening, custom IND enabling study requirements
Advanced LC-MS/MS bioanalysis supporting small molecules, lipids, peptides, and oligonucleotides (ASO, siRNA) across in vitro and in vivo matrices
Optimized siRNA, GalNAc-siRNA, oligo or mRNA delivery into hepatocytes, screening and functional read outs
Customized characterization of available hepatocyte lots, generation of custom pools from a selection of available lots
Discovery Life Sciences provides precise and accurate measurement of analytes in biological matrices to support safe, informed research decisions. We offer both qualitative and quantitative bioanalysis using state-of-the-art LC-MS/MS along with C-14 and H-3 radioactivity detection.
